Mechanism and countermeasurement of traumatic stress hyperglycemia

doi:10.3877/cma.j.issn.1674-0793.2017.05.017

Abstract

Abstract:

Stress hyperglycemia (SHG) caused by trauma is very common in clinical practice. SHG can lead to metabolic disorders, increase the risk of secondary infection after trauma, affect the body's metabolic function and cause organ damage, which seriously affects the prognosis of trauma patients and should be actively controlled. Compared with the traditional application of insulin control SHG blood glucose levels, we will discuss the potential for glucagon receptor blockers and glucagon-like peptide-1 receptor agonists to treat SHG, with the goal of less glucose variability and hypoglycaemia than with insulin.

Key words: Stress disorders, traumatic, Hyperglycemia, Receptors, glucagon, Glucagon-like peptide 1

Xiangwen Wang, Yujing Ma, Xin Zhang, Guohong Su, Mancai Wang, Youcheng Zhang. Mechanism and countermeasurement of traumatic stress hyperglycemia[J]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(05): 357-360.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2017.05.017

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2017/V11/I05/357

References 30

[1]	Barnes TM, Otero YF, Elliott AD, et al. Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas[J]. Am J Physiol Endocrinol Metab, 2014, 307(10):E896-905.
[2]	Khan AS, Gibson JM, Carlson GL, et al. Protein kinetics in human endotoxaemia and their temporal relation to metabolic, endocrine and proinflammatory cytokine responses[J]. Br J Surg, 2015, 102(7):767-775.
[3]	Harp JB,Yancopoulos GD, Gromada J. Glucagon orchestrates stress-induced hyperglycaemia[J]. Diabetes Obes Metab, 2016, 18(7):648-653.
[4]	马春霞，朱瑞，李晓娟, 等. 危重症应激性高血糖患者内毒素、NO与胰岛素组分关系的研究[J]. 宁夏医学杂志, 2017, 39(1):22-24.
[5]	Rosenbaum S, Stubbs B, Ward PB, et al. The prevalence and risk of metabolic syndrome and its components among people with posttraumatic stress disorder: a systematic review and meta-analysis[J]. Metabolism, 2015, 64(8):926-933.
[6]	Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells[J]. Diabetes, 2010, 59(4):978.
[7]	李峥，邹鑫森，李其斌,等. 全身炎症反应综合征评分结合血糖及C-反应蛋白变化对预后的预警作用[J]. 广西医学, 2013, 35(1):55-57.
[8]	金益，华文良，马渝. 严重创伤患者血糖水平与多器官功能不全综合征和感染的相关性分析[J]. 河北医学, 2015(4):549-551.
[9]	Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response![J]. Crit Care Med, 2013, 41(6):e93-94.
[10]	黄勍栋，蔡国龙，严静, 等. 重症肺炎合并高血糖患者强化胰岛素治疗的探讨[J]. 中华医院感染学杂志, 2012, 22(10):2060-2062.
[11]	倾芝娟. ICU应激性高血糖的干预管理研究[J]. 中国医药指南, 2014(35):366-367.
[12]	李轶，徐南平. 危重症神经内分泌激素的变化[J]. 实用临床医学, 2015, 16(4):104-107.
[13]	任晓红，刘虹. 血糖控制对危重症应激性高血糖患者炎症介质表达的影响[J]. 中国药物与临床, 2014, 14(3):390-392.
[14]	Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data[J]. CMAJ, 2009, 180(8):821-827.
[15]	Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients[J]. N Engl J Med, 2012, 367(12):1108-1118.
[16]	Lazar HL. How important is glycemic control during coronary artery bypass?[J]. Adv Surg, 2012, 46(1):219-235.
[17]	李林，王长强. 胰岛素强化治疗危重创伤患者应激性高血糖的效果[J]. 天津医药, 2014(4):356-358.
[18]	张永根，贺文成，杜娜. 不同血糖控制水平与ICU危重症应激性高血糖患者预后的关系研究[J]. 江西医药, 2016, 51(7):640-642.
[19]	Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma[J]. Ann Surg, 2004, 239(4):553.
[20]	Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action[J]. Diabetes, 2010, 59(7):1765.
[21]	Abuannadi M, Kosiborod M, Riggs L, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit[J]. Endocr Pract, 2013, 19(1):81-90.
[22]	Pinelli NR, Jones MC, Monday LM, et al. Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients[J]. Ann Pharmacother, 2012, 46(1):124-129.
[23]	Galiatsatos P, Gibson BR, Rabiee A, et al. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study[J]. Crit Care Med, 2014, 42(3):638-645.
[24]	Nauck MA, Walberg J, Vethacke A, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1[J]. Regul Pept, 2004, 118(1-2):89-97.
[25]	Kelly RP, Garhyan P, Raddad E, et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(4):414.
[26]	van Dongen MG, Geerts BF, Morgan ES, et al. First proof of pharmacology in humans of a novel glucagon receptor antisense drug[J]. J Clin Pharmacol, 2015, 55(3):298-306.
[27]	Kazda CM, Garhyan P, Kelly RP, et al. A randomized, double-blind, placebo-controlled phase 2 study of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes[J]. Diabetes Care, 2015, 39(7):1241.
[28]	Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover[J]. J Clin Invest, 2012, 122(1):4-12.
[29]	Guan HP, Yang X, Lu K, et al. Glucagon receptor antagonism induces increased cholesterol absorption[J]. J Lipid Res, 2015, 56(11):2183-2195.
[30]	Okamoto H, Kim J, Aglione J, et al. Glucagon receptor blockade with a human antibody normalizes blood glucose in diabetic mice and monkeys[J]. Endocrinology, 2015, 156(8):2781-2794.

Please choose a citation manager

Content to export